Tosposertib

Tosposertib is an ALK5/VEGFR2 dual inhibitor (IC50 = 1.2 nM/4.9 nM) . Tosposertib directly restores the activity of damaged cytotoxic T lymphocytes (CTLs) and natural killer cells inhibited by TGFβ and suppresses the activity and viability of regulatory T cells. Tosposertib can be used for the study of melanoma and colon cancer[1].

Product Specifications

CAS Number

[1418305-55-1]

Product Name Alternative

TU2218 (free base)

UNSPSC

12352005

Target

Anaplastic lymphoma kinase (ALK) ; VEGFR

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Purity

99.81

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=CC=CC(C(NC2=NCCN23)=C3C4=CN5N=CN=C5C=C4)=N1

Molecular Formula

C17H15N7

Molecular Weight

317.35

References & Citations

[1]Lee JY, et al., 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors. WO2013009140|[2]Kim NH, et al. ALK5/VEGFR2 dual inhibitor Tosposertib alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects. Cancer Immunol Immunother. 2024 Aug 6;73 (10) :190.